Merck to Halt Hep C Combo Trials

Oct 02, 2017

Merck announced it will discontinue developing an experimental drug combination for chronic hepatitis C, after reviewing mid-stage trial data of the treatments.

Merck made the decision about the new combo treatments (MK-3682B and MK-3682C) after reviewing their effectiveness and considering the crowded Hep C market.

The drugmaker says it will continue to study its approved treatment, Zepatier, to understand even more about its role in treating chronic hepatitis C infection.

Read the press release